The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.